Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Biofrontera Inc. to launch Phase 3 study of Ameluz-PDT » 08:51
11/21/22
11/21
08:51
11/21/22
08:51
BFRI

Biofrontera Inc.

/

+

Biofrontera announced the…

Biofrontera announced the launch of a randomized, double-blind, vehicle-controlled, multicenter Phase 3 clinical study to evaluate the safety and efficacy of Ameluz and BF-RhodoLED XL in the field-directed treatment of actinic keratosis on the extremities, neck and trunk. The study is being managed by Biofrontera Bioscience GmbH. This past weekend Biofrontera held an Investigator Meeting to train clinical investigators on the protocol for this photodynamic therapy study and prepare for site initiation. Initially 11 clinical trial sites in the U.S. will participate, enrolling approximately 165 patients stratified by body region. This study will utilize Biofrontera's new RhodoLED XL, a red-light lamp approved by the U.S. Food and Drug Administration for use in PDT in combination with Ameluz for the treatment of mild-to-moderate actinic keratosis. This lamp allows for the illumination of a larger surface area, thereby enabling simultaneous treatment of AK lesions that are distant from one another. Patients enrolled in this study will have 4-15 mild-to-moderate AK lesions in the treatment field. Each will be treated once with Ameluz-PDT and upon a three-month evaluation, will be treated a second time if any lesions remain. Investigators will continue to follow patients for 12 months after their most recent treatment to monitor for any recurrences or new lesions, as well as for any adverse events. The primary endpoint is total clearance of all lesions three months after the most recent treatment. Secondary endpoints are total clearance of all lesions three months after the last treatment by body region, percentage of all lesions cleared overall and percentage cleared by body region and severity.

ShowHide Related Items >><<
BFRI Biofrontera Inc.
/

+

BFRI Biofrontera Inc.
/

+

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
/

+

Earnings
Biofrontera Inc. reports Q3 EPS (11c) vs ($2.00) last year » 08:54
11/14/22
11/14
08:54
11/14/22
08:54
BFRI

Biofrontera Inc.

$1.00 /

+0.0547 (+5.79%)

Reports Q3 revenue…

Reports Q3 revenue $4.322M vs $4.334M last year. "During the third quarter and recent weeks we strengthened our medical affairs initiatives with sponsorship, participation and presentation of our innovative dermatology solutions. Through peer-to-peer interactions and other activities, dermatologists are increasingly choosing our brands for their patients. The variety of our activities and our visibility in the dermatology sector are sharpening our corporate profile as an innovative dermatology company and emphasizing our strong commitment to improving patient care in collaboration with dermatologists. Our success in strengthening patent protection for our products justifies continued investments in marketing and further clinical development," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. "Key strategic hires including a CFO and a national sales director will support our continued success. With year-to-date revenues up 24%, we expect total revenues for 2022 to increase between 24% and 31% compared with 2021, inclusive of seasonal strength in the first and fourth quarters. We expect to close 2022 with demonstrated market-share gains as well as with an operational foundation that will position us for increased ROI in 2023."

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.00 /

+0.0547 (+5.79%)

BFRI Biofrontera Inc.
$1.00 /

+0.0547 (+5.79%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.00 /

+0.0547 (+5.79%)

Over a month ago
Syndicate
Biofrontera Inc. files to sell 7.43M shares of common stock for holders  06:09
11/03/22
11/03
06:09
11/03/22
06:09
BFRI

Biofrontera Inc.

$1.05 /

-0.025 (-2.34%)

 
ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.05 /

-0.025 (-2.34%)

BFRI Biofrontera Inc.
$1.05 /

-0.025 (-2.34%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.05 /

-0.025 (-2.34%)

BFRI Biofrontera Inc.
$1.05 /

-0.025 (-2.34%)

Hot Stocks
Biofrontera enters into agreements to purchase options of Biofrontera AG » 08:59
10/31/22
10/31
08:59
10/31/22
08:59
BFRI

Biofrontera Inc.

$1.07 /

-0.02 (-1.83%)

Biofrontera announced it…

Biofrontera announced it has entered into private exchange agreements with certain holders of options to acquire ordinary shares of Biofrontera AG in exchange for 3,148,042 newly issued shares of Biofrontera common stock. The AG Options represent the right to acquire 2,623,365 ordinary shares of Biofrontera AG held by the shareholders, or approximately 4.63% of Biofrontera AG's outstanding ordinary shares. "This transaction represents a major milestone in the strategic positioning of Biofrontera Inc. We strive to distinguish ourselves as an independent U.S. based biopharmaceutical company, exclusively serving the world's largest dermatology market," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. "The agreements will further strengthen our position and realize our full commercial potential in this fast-growing market. At the same time, the transaction underscores the strength of our relationship with our former parent company Biofrontera AG. As the key driver of Biofrontera AG's products' sales growth and their largest source of revenue, we will continue to work together closely," she added. "This will enable us to support our mutually beneficial interests, especially in the areas of intellectual property, manufacturing, regulatory affairs and clinical trials."

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.07 /

-0.02 (-1.83%)

BFRI Biofrontera Inc.
$1.07 /

-0.02 (-1.83%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.07 /

-0.02 (-1.83%)

BFRI Biofrontera Inc.
$1.07 /

-0.02 (-1.83%)

Hot Stocks
Biofrontera Inc. appoints Fred Leffler as CFO » 07:46
10/24/22
10/24
07:46
10/24/22
07:46
BFRI

Biofrontera Inc.

$1.21 /

-0.02 (-1.63%)

Biofrontera announces the…

Biofrontera announces the appointment of Fred Leffler as CFO, effective immediately. Most recently, Mr. Leffler was a Senior Manager at McKinsey & Company in Boston, having served in a similar capacity in their Washington, D.C. office earlier in his career.

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.21 /

-0.02 (-1.63%)

BFRI Biofrontera Inc.
$1.21 /

-0.02 (-1.63%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.21 /

-0.02 (-1.63%)

  • 29
    Oct
BFRI Biofrontera Inc.
$1.21 /

-0.02 (-1.63%)

Hot Stocks
Biofrontera Inc. adopts limited duration shareholder rights plan » 08:41
10/14/22
10/14
08:41
10/14/22
08:41
BFRI

Biofrontera Inc.

$1.15 /

+0.04 (+3.60%)

Biofrontera announced…

Biofrontera announced that its Board of Directors has adopted a limited duration shareholder rights plan, and declared a dividend distribution of one preferred stock purchase right on each outstanding share of common stock, in order to protect the interest of all of the Company's shareholders. The rights will be issued to shareholders of record on October 24, 2022 and will expire on October 13, 2023. The Board believes that the current price of the Company's common stock is not reflective of the Company's intrinsic or long-term value. The Board further believes the Rights Plan is an effective course of action to fulfill its fiduciary duties to the Company and its shareholders, and to enable shareholders to realize the long-term value of their investment. The Rights Plan was adopted following a careful evaluation and consultation with the Company's external legal and financial advisors. The Rights Plan is similar to plans adopted by other publicly traded companies. Pursuant to the Rights Plan, the Company will distribute one right for each share of common stock outstanding as of the close of trading on October 24, 2022. While the Rights Plan is effective immediately, the rights would become exercisable only if a person or group, or anyone acting in concert with such a person or group, acquires beneficial ownership, as defined in the Rights Plan, of 20% or more of the Company's issued and outstanding common stock in a transaction not approved by the Company's Board of Directors. In that situation, each holder of a right (other than the acquiring person or group, or anyone acting in concert as defined in the Rights Plan with such person or group), will have the right to purchase a number of shares of Company common stock at an exercise price of one-half the market value of the right. In addition, at any time after a person or group acquires 20% or more of the Company's common stock, unless such person or group acquires 50% or more, the Company's Board of Directors may exchange one share of the Company's common stock for each outstanding right, other than rights owned by such person or group, which would have become void.

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.15 /

+0.04 (+3.60%)

BFRI Biofrontera Inc.
$1.15 /

+0.04 (+3.60%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.15 /

+0.04 (+3.60%)

  • 29
    Oct
BFRI Biofrontera Inc.
$1.15 /

+0.04 (+3.60%)

Hot Stocks
Biofrontera Inc. sees Q3 product revenue at about $4.3M » 17:01
10/05/22
10/05
17:01
10/05/22
17:01
BFRI

Biofrontera Inc.

$1.13 /

+0.04 (+3.67%)

The company states:…

The company states: "Product revenues for the third quarter of 2022 are anticipated to be approximately $4.3 million, consistent with the third quarter of 2021. These projections result in product revenues for the first nine months of 2022 expected to be approximately $18.5 million up approximately 24% compared with the first nine months of 2021. Year-to-date 2022 product revenues are at a record high, and are up approximately 26% over the comparable period in the pre-Covid year 2019."

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.13 /

+0.04 (+3.67%)

BFRI Biofrontera Inc.
$1.13 /

+0.04 (+3.67%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.13 /

+0.04 (+3.67%)

  • 29
    Oct
BFRI Biofrontera Inc.
$1.13 /

+0.04 (+3.67%)

BFRI Biofrontera Inc.
$1.13 /

+0.04 (+3.67%)

Hot Stocks
Biofrontera Inc. appoints Gerard DiGirolamo as national sales director » 08:32
09/13/22
09/13
08:32
09/13/22
08:32
BFRI

Biofrontera Inc.

$1.24 /

-0.01 (-0.80%)

Biofrontera announces the…

Biofrontera announces the appointment of Gerard DiGirolamo as National Sales Director. In this newly created position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera's Head of Sales & Marketing, and will help execute the Company's U.S. sales division and objectives including the strategic design, expansion and leadership of its sales team. He will oversee recruiting and staffing to support Ameluz, BF-RhodoLED and Xepi commercial efforts, as well as spearhead planning for the launch of BF-RhodoLED XL. Most recently he served as Vice President of Sales at Verrica Pharmaceuticals.

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.24 /

-0.01 (-0.80%)

BFRI Biofrontera Inc.
$1.24 /

-0.01 (-0.80%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.24 /

-0.01 (-0.80%)

  • 29
    Oct
BFRI Biofrontera Inc.
$1.24 /

-0.01 (-0.80%)

BFRI Biofrontera Inc.
$1.24 /

-0.01 (-0.80%)

Hot Stocks
Biofrontera Inc. announces notice of allowance for nanoemulsion patent » 10:33
09/06/22
09/06
10:33
09/06/22
10:33
BFRI

Biofrontera Inc.

$1.19 /

-0.01 (-0.83%)

Biofrontera Inc.…

Biofrontera Inc. announced that the United States Patent and Trademark Office has granted a notice of allowance to Biofrontera Bioscience GmbH for patent application No. 12/520,759, titled "Nanoemulsion Formulation with Improved Stability and Cell Penetration." Biofrontera Inc. has an exclusive license to market and sell Ameluz, an FDA-approved drug utilizing the technology covered by the patent, in the U.S. The '759 patent relates to the compositions of Biofrontera's nanoemulsions and an active agent and the preparation of the nanoemulsions or compositions, and describes its use in the treatment of dermatological, virus-associated and cell proliferation diseases, as well as in cosmetics. Biofrontera's compositions of nanoemulsions overcome the disadvantages of other nanoemulsion formulations through a reduced particle size that contributes to improved stability, better penetration into cells and tissues and lower production costs. "This new patent will further protect Biofrontera's growing position in the dermatology market and our continued investment in the market. Compound-of-matter patents provide the strongest protection of all patent types. Our license agreement covers all combinations of the patented nanoemulsion technology with aminolevulinic acid, the active ingredient in Ameluz. Together with Biofrontera Bioscience we are now even more strongly positioned to broaden the use of photodynamic therapy in dermatology," stated Hermann Lubbert, Executive Chairman of Biofrontera Inc.

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.19 /

-0.01 (-0.83%)

BFRI Biofrontera Inc.
$1.19 /

-0.01 (-0.83%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.19 /

-0.01 (-0.83%)

  • 29
    Oct
BFRI Biofrontera Inc.
$1.19 /

-0.01 (-0.83%)

BFRI Biofrontera Inc.
$1.19 /

-0.01 (-0.83%)

Over a quarter ago
Hot Stocks
Biofrontera Inc. expects cash to fund operations for at least next 12 months » 08:37
08/12/22
08/12
08:37
08/12/22
08:37
BFRI

Biofrontera Inc.

$1.38 /

-0.03 (-2.13%)

As of June 30, 2022,…

As of June 30, 2022, Biofrontera Inc. had cash and cash equivalents of $31.9 million, compared with $24.5 million as of December 31, 2021. The Company believes its cash and cash equivalents are sufficient to fund operations for at least the next 12 months.

ShowHide Related Items >><<
BFRI Biofrontera Inc.
$1.38 /

-0.03 (-2.13%)

BFRI Biofrontera Inc.
$1.38 /

-0.03 (-2.13%)

12/30/21 Benchmark
Biofrontera AG financial reporting may now change, says Benchmark
12/15/21 Benchmark
Biofrontera initiated with a Buy at Benchmark
11/24/21 Roth Capital
Roth Capital bullish on Biofrontera, initiates with a Buy
11/24/21 Roth Capital
Biofrontera initiated with a Buy at Roth Capital
BFRI Biofrontera Inc.
$1.38 /

-0.03 (-2.13%)

  • 29
    Oct
BFRI Biofrontera Inc.
$1.38 /

-0.03 (-2.13%)

BFRI Biofrontera Inc.
$1.38 /

-0.03 (-2.13%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.